Suppr超能文献

慢性阻塞性肺疾病的皮质类固醇治疗。其风险是否值得?

Corticosteroid therapy for chronic obstructive pulmonary disease. Is it worth the risks?

作者信息

Alberts W M, Corrigan K C

出版信息

Postgrad Med. 1987 Apr;81(5):131-4, 137. doi: 10.1080/00325481.1987.11699788.

Abstract

The majority of patients with chronic obstructive pulmonary disease (COPD) do not appear to benefit from long-term corticosteroid therapy. Nevertheless, a small minority demonstrate a response to treatment that is so dramatic that it may be worth the risk of chronic corticosteroid use. A corticosteroid trial is indicated in the patient with COPD who remains symptomatic despite adequate and aggressive routine treatment. If substantial improvement is noted in pulmonary function, chronic corticosteroid treatment should be considered. In patients without an objective response, long-term corticosteroid therapy should not be continued.

摘要

大多数慢性阻塞性肺疾病(COPD)患者似乎无法从长期使用皮质类固醇激素治疗中获益。然而,少数患者对治疗的反应非常显著,以至于使用皮质类固醇激素带来的长期风险可能是值得的。对于尽管接受了充分且积极的常规治疗仍有症状的COPD患者,建议进行皮质类固醇激素试验。如果肺功能有显著改善,则应考虑长期使用皮质类固醇激素治疗。对于没有客观反应的患者,不应继续进行长期皮质类固醇激素治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验